Statin use has been shown to reduce cardiovascular disease (CVD) and provide a survival benefit in the HIV-negative general population. However, the risk factors for CVD are somewhat different for people living with HIV. The question is being addressed by the REPRIEVE study, a very large multicentre clinical trial which is now getting underway. However, even before the results of this trial are in, evidence is mounting that statin therapy can prevent the progression of coronary atherosclerosis (hardening and narrowing of the arteries supplying the heart) in people living with HIV.
You can read the full article here.